Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
Vaccines

Serum Bactericidal Assays To Evaluate Typhoidal and Nontyphoidal Salmonella Vaccines

Mary Adetinuke Boyd, Sharon M. Tennant, Venant A. Saague, Raphael Simon, Khitam Muhsen, Girish Ramachandran, Alan S. Cross, James E. Galen, Marcela F. Pasetti, Myron M. Levine
D. L. Burns, Editor
Mary Adetinuke Boyd
aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
cDepartment of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon M. Tennant
aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
bDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venant A. Saague
aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
bDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphael Simon
aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
bDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khitam Muhsen
aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
bDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Girish Ramachandran
aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
bDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan S. Cross
aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
bDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James E. Galen
aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
bDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcela F. Pasetti
aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
cDepartment of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myron M. Levine
aCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
bDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
cDepartment of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. L. Burns
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CVI.00115-14
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Survival of Salmonella spp. in the presence of complement alone. Survival of S. Typhimurium D65, S. Enteritidis R11, S. Typhi Ty2, and S. Paratyphi A ATCC 9150 in the presence of guinea pig complement (GPC) (A) and baby rabbit complement (BRC) (B) in the absence of immune sera. The results are the mean ± standard deviation values from at least two independent experiments. The dashed line represents 100% of inoculum as a visual reference.

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    Complement titrations. Shown is the survival of S. Typhimurium D65 (A), S. Enteritidis R11 (B), S. Typhi Ty2 (C), all grown to log phase (OD600, 0.4), and S. Paratyphi A ATCC 9150 (D) grown to stationary phase with BRC in the presence of immune (I) compared to nonimmune (NI) sera and decreasing complement concentrations. The results are shown as the mean ± standard deviation values from more than three independent experiments. *, P < 0.05, and **, P < 0.01, by Student's t test (two-tailed). The dashed lines represent 100% of inoculum as a visual reference.

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    Survival of S. Typhimurium in the presence of complement from various animals and antibody. Shown is the survival of S. Typhimurium D65 in the presence of immune (I) antibody compared to nonimmune (NI) antibody with indicated complement sources. The results are the mean ± standard deviation values from more than three independent experiments. BRC is from 3- to 4-week-old rabbits. **, P < 0.01 by the Mann-Whitney test. The dashed line represents 100% of inoculum as a visual reference.

  • FIG 4
    • Open in new tab
    • Download powerpoint
    FIG 4

    LPS produced by Salmonella serovar. (A) LPS profiles of S. Typhimurium D65 (lane 1), S. Enteritidis R11 (lane 2), S. Typhi Ty2 (lane 3), and S. Paratyphi A ATCC 9150 (lane 4) after overnight culture. Ratio of long or medium O antigen (O-Ag) at OD600 of 0.4, 0.8, and 4.0 to overnight culture for S. Typhimurium D65 (B), S. Enteritidis R11 (C), S. Typhi Ty2 (D), and S. Paratyphi A ATCC 9150 (E). The results are the mean ± standard deviation values from more than three independent experiments. *, P < 0.05, **, P < 0.01, and ***, P < 0.001, by ANOVA, with Bonferroni's test for multiple comparison.

  • FIG 5
    • Open in new tab
    • Download powerpoint
    FIG 5

    SBA titer and presence of the gene rck. SBA titers in pooled sera from CVD 1941-immunized mice against clinical invasive rck-positive or rck-negative S. Enteritidis strains. The lines represent the mean titers from at least three independent experiments. P = 0.45, Student's t test, two-tailed. n.s., nonsignificant.

  • FIG 6
    • Open in new tab
    • Download powerpoint
    FIG 6

    Survival of S. Typhi strains that express various levels of Vi in the presence of BRC. Shown is the survival of S. Typhi strains Ty2 and CVD 909 grown to an OD600 of 0.4 and incubated with 12.5% BRC in the absence of immune serum. The results represent the mean ± standard deviation value from at least three independent experiments. c, constitutively expressed. *, P < 0.05 and **, P < 0.01, by Student's t test, two-tailed. The dashed line represents 100% of inoculum as a visual reference.

  • FIG 7
    • Open in new tab
    • Download powerpoint
    FIG 7

    Endpoint SBA titers for mice immunized with live attenuated typhoidal and nontyphoidal Salmonella vaccines. (A) Sera from mice immunized with S. Typhimurium CVD 1931 against the target strain S. Typhimurium D65. (B) Sera from mice immunized with S. Enteritidis CVD 1944 against the target strain S. Enteritidis S15. (C) Sera from mice immunized with S. Typhi CVD 910 against the target strain S. Typhi Ty2. (D) Sera from mice immunized with S. Paratyphi A CVD 1902 against the target strain S. Paratyphi A ATCC 9150. The solid lines indicate mean titers. The dashed lines indicate the detection limit of the assay. **, P < 0.01, and ****, P < 0.0001, by the Mann-Whitney test.

  • FIG 8
    • Open in new tab
    • Download powerpoint
    FIG 8

    Correlation of SBA titer with anti-LPS serum IgG titer. SBA and anti-LPS serum titers produced by mice immunized with S. Typhimurium CVD 1931 (A), S. Enteritidis CVD 1944 (B), S. Typhi CVD 910 (C), and S. Paratyphi A CVD 1902 (D). The data were analyzed using Spearman's correlation coefficient.

  • FIG 9
    • Open in new tab
    • Download powerpoint
    FIG 9

    SBA titers using attenuated or reference Salmonella strains. Shown in black are the SBA titers produced by mice immunized with S. Typhimurium CVD 1931 (n = 12, pooled) using S. Typhimurium strains D65 and D23580 as target strains; in gray are the SBA titers produced by mice immunized with S. Paratyphi A CVD 1902 (n = 10, pooled) using S. Paratyphi A strains ATCC 9150 and CVD 1901 as target strains; in white are the SBA titers produced by mice immunized with S. Typhi CVD 910 (n = 12, pooled) using S. Typhi strains Ty2 and CVD 915 as target strains. The results are the mean ± standard deviation values from at least two independent experiments.

Tables

  • Figures
  • Additional Files
  • TABLE 1

    Bacterial strains used in this study

    Serovar or speciesStrainIsolation location or characteristicsReference(s) or source
    Salmonella TyphimuriumD65Clinical isolate from blood culture, Mali43, 44
    D23580Clinical isolate from blood culture, Malawi18, 45
    CVD 1921I77 ΔguaBA ΔclpP15
    CVD 1931D65 ΔguaBA ΔclpXS. M. Tennant, P. Schmidlein, J. E. Galen, and M. M. Levine, unpublished data
    Salmonella EnteritidisR11Clinical isolate from blood culture, Mali43, 44
    S01Clinical isolate from blood culture, Mali43, 44
    S15Clinical isolate from blood culture, Mali43, 44
    Q38Clinical isolate from blood culture, Mali43, 44
    CVD 1941R11 ΔguaBA ΔclpP15
    CVD 1944R11 ΔguaBA ΔclpX15
    Salmonella TyphiTy2Wild-type46
    CVD 909Ty2 ΔaroC ΔaroD ΔhtrA Ptac-tviA11
    CVD 910Ty2 ΔguaBA ΔhtrA26
    CVD 915Ty2 ΔguaBA47
    Ty21aTy2 ΔgalE ΔilvD ΔviaB (Vi−) H2S−48
    Salmonella Paratyphi AATCC 9150Wild-typeAmerican Type Culture Collection, Manassas, VA
    CVD 1901ATCC 9150 ΔguaBA14
    CVD 1902ATCC 9150 ΔguaBA ΔclpX14
    Escherichia coliBortO18:K1:H7, clinical isolate from blood culture, Walter Reed Army Medical Center49
  • TABLE 2

    Optimized SBA assay conditions for typhoidal and nontyphoidal Salmonella

    Salmonella serovarGrowth phaseNo. of CFU% BRC
    TyphimuriumLog (OD600 of 0.4)100–35025
    EnteritidisLog (OD600 of 0.4)100–35025
    TyphiLog (OD600 of 0.4)100–35012.5
    Paratyphi AStationary100–35012.5

Additional Files

  • Figures
  • Tables
  • Supplemental material

    Files in this Data Supplement:

    • Supplemental file 1 -

      Fig. S1. Growth curve of Salmonella serovars S. Typhimurium D65, S. Enteritidis R11, S. Typhi Ty2, and S. Paratyphi A ATCC 9150. Fig. S2. Example of LPS gel used for densitometry analysis.

      PDF, 186K

PreviousNext
Back to top
Download PDF
Citation Tools
Serum Bactericidal Assays To Evaluate Typhoidal and Nontyphoidal Salmonella Vaccines
Mary Adetinuke Boyd, Sharon M. Tennant, Venant A. Saague, Raphael Simon, Khitam Muhsen, Girish Ramachandran, Alan S. Cross, James E. Galen, Marcela F. Pasetti, Myron M. Levine
Clinical and Vaccine Immunology May 2014, 21 (5) 712-721; DOI: 10.1128/CVI.00115-14

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Serum Bactericidal Assays To Evaluate Typhoidal and Nontyphoidal Salmonella Vaccines
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Serum Bactericidal Assays To Evaluate Typhoidal and Nontyphoidal Salmonella Vaccines
Mary Adetinuke Boyd, Sharon M. Tennant, Venant A. Saague, Raphael Simon, Khitam Muhsen, Girish Ramachandran, Alan S. Cross, James E. Galen, Marcela F. Pasetti, Myron M. Levine
Clinical and Vaccine Immunology May 2014, 21 (5) 712-721; DOI: 10.1128/CVI.00115-14
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X